FORMAC appoints new CEO
01-Dec-2009
- Belgium
Jan Rosier joins FORMAC from Johnson & Johnson where he was Vice President Infectious Diseases ChemPharm Development. At Johnson & Johnson he was instrumental to many successes of the TIBOTEC portfolio including the development and approval of PREZISTA and INTELENCE in HIV, the progress of telaprevir (VX-950) and TMC435 in hepatitis C and of TMC207 in tuberculosis.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.